Latest news and press releases about ProKidney Corp. (PROK): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease.
Price
| Price | $1.85 |
| Market Cap | $622M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | -0.39 |
| EV / EBITDA | -3.41 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 8.83% |
| Return on Invested Capital | -68.08% |
| Return on Assets | -34.82% |
| Gross Margin | -252.57% |
| Operating Margin | -21664.55% |
| Net Margin | -10599.76% |
Related companies: BCAX · EYPT · KURA · NBTX · PRME · RZLT · SEPN
Explore sector: Healthcare · Biotechnology
More sections of PROK: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks